53856-93-2

Upstream product

• 186581-53-3 diazomethane 
• 61882-39-1 4-methoxy-butyryl chloride 
• 67-56-1 methanol 
• 123-76-2 levulinic acid 
• 7770-06-1 methyl 5-diazo-4-oxopentanoate 
• 109988-02-5 2-methoxycarbonylethyl (trimethylsilyl)methyl ketone 
• 52944-79-3 3,3'-Dimethoxycarbonylpropanoic anhydride 
• 3878-55-5 methyl hydrogen succinate 
• 1490-25-1 succinic acid monomethylester chloride 
• 624-45-3 levulinic acid methyl ester 
• 539-88-8 4-oxopentanoic acid ethyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 109258-71-1 methyl 5-(1,3-dioxoisoindolin-2-yl)-4-oxopentanoate 
• 125736-39-2 (S)-1-Benzyl-5-[4-methoxycarbonyl-2-oxo-but-(E)-ylidene]-pyrrolidine-2-carboxylic acid tert-butyl ester 
• 125736-40-5 (R)-1-Benzyl-5-[4-methoxycarbonyl-2-oxo-but-(E)-ylidene]-pyrrolidine-2-carboxylic acid tert-butyl ester 
• 115663-40-6 (E)-6-(5-Chloro-2-nitro-phenyl)-4-oxo-hex-5-enoic acid methyl ester 
• 141856-29-3 Methyl 5-amino>-4-oxopentanoate 
• 141856-07-7 Methyl 5-amino>-4-oxopentanoate 
• 141856-25-9 Methyl 5-amino>-4-oxopentanoate 
• 84028-78-4 (5-methoxy-2,5-dioxopentyl)triphenylphosphonium bromide 
• 943323-19-1 C₃₂H₅₀O₉SSi₂ 
• 943322-80-3 C₃₃H₄₆O₁₀S 
• 701262-90-0 (E)-6-{(4R,5S)-2,2-Dimethyl-5-[(1S,2S)-2-(toluene-4-sulfonyloxy)-1-triethylsilanyloxy-but-3-ynyl]-[1,3]dioxolan-4-yl}-4-oxo-hex-5-enoic acid methyl ester 
• 701262-89-7 (E)-6-{(4R,5S)-2,2-Dimethyl-5-[(1S,2S)-2-(toluene-4-sulfonyloxy)-1-triethylsilanyloxy-4-trimethylsilanyl-but-3-ynyl]-[1,3]dioxolan-4-yl}-4-oxo-hex-5-enoic acid methyl ester 
• 99310-57-3 4-(2-carboxyethyl)imidazolin-2-one 
• 79416-27-6 methyl aminolevulinate 

Relevant academic research and scientific papers

Radiochemical Synthesis and Evaluation of 13N-Labeled 5-Aminolevulinic Acid for PET Imaging of Gliomas

The endogenous amino acid, 5-aminolevulinic acid (5-ALA), has received significant attention as an imaging agent, including ongoing clinical trials for image-guided tumor resection due to its selective uptake and subsequent accumulation of the fluorescent protoporphyrin IX in tumor cells. Based on the widely reported selectivity of 5-ALA, a new positron emission tomography imaging probe was developed by reacting methyl 5-bromolevulinate with [13N] ammonia. The radiotracer, [13N] 5-ALA, was produced in high radiochemical yield (65%) in 10 min and could be purified using only solid phase cartridges. In vivo testing in rats bearing intracranial 9L glioblastoma showed peak tumor uptake occurred within 10 min of radiotracer administration. Immunohistochemical staining and fluorescent imaging was used to confirm the tumor location and accumulation of the tracer seen from the PET images. The quick synthesis and rapid tumor specific uptake of [13N] 5-ALA makes it a potential novel clinical applicable radiotracer for detecting and monitoring tumors noninvasively.

Selective bromination of ketones. A convenient synthesis of 5-aminolevulinic acid

Bromination of unsymmetrical ketones with Br2 in methanol proceeded regioselectively in good yield at the less substituted methyl carbon. The bromination of levulinic acid using this method was followed by azidation and amination to lead to an efficient three-step synthesis of 5-aminolevulinic acid in 36% overall yield.

Synthesis and characterization of altaicadispirolactone

Altaicadispirolactone was synthesized via a simple route. In this route, levulinic acid was used as a starting material, and bromination followed by hydrolysis and BF3·OEt2-catalyzed cyclization were carried out. A single-crystal ORTEP drawing has been created and more detailed crystallographic data of the compound has been obtained from X-ray analysis. Copyright Taylor & Francis, Inc.

N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT

N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used without side effects for efficient prevention and treatment of diseases mediated by IRAK-4 receptors, particularly autoimmune diseases or lymphomas.

Preparation method 5 - ALA intermediate 5 - bromoolevulinic acid ester

The invention relates to a preparation method of 5 - ALA intermediate 5 - bromoacetyl ester, which is characterized by comprising the following steps: (S1) reaction of the urotropine and a bromine source to prepare the urotropine bromine complex. (S2) Lourotropine bromide complex and levulinic acid ester reaction. Gave 5 - bromoolevulinic acid ester. Compared with the prior art, a bromo reagent such as liquid bromine and 5 - is used directly, NBS-site bromination product yield is increased 5 - 10% or more. The defect that 3 -position bromination or multi-site bromination product is large and separation is difficult in the bromination reaction is overcome. The method is cheap and easily available in raw materials, simple and convenient to operate and suitable for large-scale preparation 5 - ALA intermediate 5 - bromolevulinic acid ester .

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors

Several human diseases are associated with aberrant epigenetic pathways mediated by histone deacetylases (HDACs), especially HDAC6, a class IIb HDACs, which has emerged as an attractive target for neurodegenerative and autoimmune disease therapeutics. In a previous study, we developed the novel HDAC6-selective inhibitor 9a ((E)-N-hydroxy-4-(2-styrylthiazol-4-yl)butanamide) and showed that it has anti-sepsis activity in vivo. In this study, we conducted structure-activity relationship (SAR) studies to optimize the activity and selectivity of HDAC6, synthesizing its derivatives with various aliphatic linker sizes and cap structures. We identified 6u ((E)-N-hydroxy-3-(2-(4-fluorostyryl)thiazol-4-yl)propanamide), which has nanomolar inhibition activity and a 126-fold selectivity for HDAC6 over HDAC1. Through the docking analyses of 6u against HDAC subtypes, we revealed the importance of the optimal aliphatic linker size, as well as the electronic substituent effect and rigidity of the aryl cap group. Thus, we suggest a new rationale for the design of HDAC6-selective inhibitors.

Method for manufacturing methyl 5-bromolevulinate and manufacturing method 5-aminolevulinic acid heyl ester hydrochloride using the same

The present invention relates to a method of preparing methyl 5-bromolevulinate, capable of improving the yield of a final product while having stability of a product, and a method of preparing 5-aminoalkylenic acid hexyl ester hydrochloride using the same. To this end, the method of preparing methyl 5-bromolevulinate comprises: a first reaction step of mixing levulinic acid, methanol and bromine in a container and making the mixture react; a second reaction step of mixing a first product of the first reaction step, a first reactant not reacting in the first reaction step, ultrapure water and chloroform solution, and making the mixture react; an extraction step of extracting a chloroform solution layer from a first mixture formed after the second reaction step; a third reaction step of mixing the chloroform solution layer extracted in the extraction step, ethyl ether, and sodium bicarbonate saturated aqueous solution and stirring the mixture; a purification step of separating an aqueous solution layer from a second mixture formed after the third reaction step; a fourth reaction step of mixing a remaining mixture after the aqueous solution layer is separated from the second mixture with N-Hexane, and making the mixture react; a precipitation step of precipitating methyl 5-bromolevulinate in a solid state from a third mixture while quenching the third mixture formed after the fourth reaction step; and a filtering step of filtering the methyl 5-bromolevulinate in the solid state from a fourth mixture formed after the precipitation step by using a filtration device.COPYRIGHT KIPO 2019

Synthesis of 5-aminolevulinic acid with nontoxic regents and renewable methyl levulinate

Synthesis of 5-aminolevulinic acid (5-ALA) was presented with novel bromination of biobased methyl levulinate (ML), followed by ammoniation and hydrolysis. Copper bromide (CuBr2) was employed as the bromination reagent with higher selectivity and activity instead of the conventional liquid bromine (Br2). 5-ALA was obtained in a high yield (64%) and purity (>95%) by optimum design, which is of great potential in industrialization.

Multifunctional Cyclopentadienes as a Scaffold for Combinatorial Bioorganometallics in [(η5-C5H2R1R2R3)M(CO)3] (M=Re, 99mTc) Piano-Stool Complexes

Multifunctional cyclopentadiene (Cp) ligands and their rhenium and 99mTc complexes were prepared by a versatile synthetic route. The properties of these Cp ligands can be tuned on demand, either during their synthesis (variation of R1) or through post-synthetic functionalization with two equal or different vectors (V1 and V2). Variation of these groups enables a combinatorial approach in the synthesis of bioorganometallic complexes. This is demonstrated by the preparation of Cp ligands containing both electron-donating and electron-withdrawing groups at the R1 position and their subsequent homo- or heterofunctionalization with biovector models (benzylamine and phenylalanine) under standard amide bond-formation conditions. All ligands can be coordinated to the fac-[Re(CO)3]+ and fac-[99mTc(CO)3]+ cores to give tetrafunctional complexes in straightforward and functional-group-tolerant procedures. The 99mTc complexes were prepared in one step, in 30 min, and under aqueous conditions from generator-eluted [99mTcO4]?.